Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/046497
Kind Code:
A3
Abstract:
This disclosure is directed to a pharmaceutical composition comprising a bioactive agent (active pharmaceutical ingredient, API) and at least one long chain fatty acid (LCFA), wherein the long chain fatty acid can comprise a carbon chain having at least 10 carbon atoms and can comprise a free carboxylic acid group or a salt thereof. The LCFA-conjugated active pharmaceutical ingredient (API) can be resistant to acid degradation in digestive system and facilitate the delivery of the API across the small intestinal epithelial cell membrane via fatty acid transport protein 4 (FATP4, also known as SLC27A4). The pharmaceutical composition can be formulated in acid- resistant (enteric-release) dosage forms for oral administration in patients. This disclosure is further directed to a process for producing the LCFA-conjugated bioactive agent including protein, polypeptide, small molecule drugs, DNA, RNA, oligonucleotide, or a combination thereof.

Inventors:
SHEN HAIFA (US)
Application Number:
PCT/US2020/049609
Publication Date:
April 01, 2021
Filing Date:
September 06, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHEN HAIFA (US)
International Classes:
A61K38/22; C07H13/06
Foreign References:
US20110082079A12011-04-07
Other References:
CHAE ET AL.: "The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics", JOURNAL OF CONTROLLED RELEASE, vol. 144, no. 1, 21 May 2010 (2010-05-21), pages 10 - 16, XP027036550
Attorney, Agent or Firm:
XU, Gann G. (US)
Download PDF: